seladelpar
AssetSmall molecule
Selective PPAR-delta receptor agonist that regulates bile acid synthesis, inflammation, and lipid metabolism.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- Indications
- 1
- Trials
- 1
- Developers
- 1
Indications
1Primary biliary cholangitis
Phase 3RECRUITINGNCT06051617clinicaltrials.gov7 Oct 2026
- Targets and what it contains3
- Owner and partners1
- Trials1
- Evidence for its targets3
- Competitors3
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 1 source